Stocksigma LogoStocksigma Logo

Akums Drugs Reports Strong Q2 FY27 Financial Results

Akums Drugs & Pharmaceuticals delivered robust Q2 FY27 results, with revenue growing 31.9% YoY to ₹1,342 crore and PAT surging 168% YoY to ₹115 crore

Akums Drugs Reports Strong Q2 FY27 Financial Results

Akums Drugs and Pharmaceuticals Ltd · Press Release · 02 Nov 2026, 11:34 pm

Akums Drugs Reports Strong Q2 FY27 Financial Results Akums Drugs & Pharmaceuticals delivered robust Q2 FY27 results, with revenue growing 31.9% YoY to ₹1,342 crore and PAT surging 168% YoY to ₹115 crore. EBITDA rose 106% YoY to ₹195 crore, expanding margins to 14.5% from 9.3%. The CDMO segment drove growth, with revenue up 38.6% YoY to ₹1,115 crore and EBITDA up 99.6% YoY to ₹168 crore. The company acquired Oriflame India’s manufacturing business for ₹56 crore to enter cosmetics and holds an active pipeline of 30+ European products.

Original exchange filing (PDF)

More announcements from Akums Drugs and Pharmaceuticals Ltd

All Akums Drugs and Pharmaceuticals Ltd announcements